Impaired PBPC collection in patients with myeloma after high-dose melphalan

References

• Attal M, Harousseau JL, Facon T et al . Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003;349: 2495 –/502.
   Google Scholar
• Barlogie B, Jagannath S, Vesole D et al . Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89: 789–/93.
   Google Scholar
• Nichols CR, Tricot G, Williams SD et al . Dose-intensive chemotherapy in refractory germ cell cancer: a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989;7: 932–/9.
   Google Scholar
• Ayash LJ, Elias A, Schwartz G et al . Double dose-intensive chemotherapy with autologous stem cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclohosphamide, thiotepa, and carboplatin. J Clin Oncol 1996;14: 2984–/92.
   Google Scholar
• Akard LP, Wiemann M, Thompson JM et al . Impaired stem cell collection by consecutive courses of high-dose mobilizing chemotherapy using cyclophosphamide, etoposide and G-CSF. MJ Hematother 1996;5: 272–/7.
   Google Scholar
• Sutherland DR, Anderson L, Keeney M et al . The ISHAGE guidelines for CD34–/ cell determination by flow cytometry. J Hematother 1996;5: 213–/26.
   Google Scholar
• Goldstone AH, Gribben JG, Linch DC et al . Double autografting as potential curative therapy for acute leukemia. In: Dicke KA, Spitzer G, Jagannath S, editors. Autologous Bone Marrow Transplantation III, University of Texas, Houston, TX, 1987:111–/8.
   Google Scholar
• Vescio R, Schiller G, Stewart AK et al . Multicenter phase III trial to evaluate CD34– selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999;93: 1858–/68.
   Google Scholar
• Zhou P, Zhang Y, Klakonda N et al . Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination. Blood 2003;102: 477 –/9.
   Google Scholar
• Morris CL, Siegel E, Barlogie B et al . Mobilization of CD34– cells in elderly patients (]/ 70 years) with multiple myelomainfluence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003;120: 413–/23.
   Google Scholar
• Desikan KR, Tricot G, Munshi NC et al . Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony stimulating factor alone. Br J Haematol 2001;112: 242 –/7.
   Google Scholar
• Meisenberg B, Brehm T, Schmeckel A et al . A combination of low-dose cyclophosphamide and colony-stimulating factor is more cost-effective than granulocyte colony-stimulating factors alone in mobilizing peripheral blood stem and progenitor cells. Transfusion 1998;38: 209–/15.
   Google Scholar
• Narayanasami U, Kantell R, Morelli J et al . Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001;98:2059 –/64.
   Google Scholar
• Koc� ON, Gerson SL, Cooper BW et al . Randomized cross-overtrial of progenitor cell mobilization: high-dose cyclophosphamideplus granulocyte colony-stimulating factor (G-CSF)versus granulocyte-macrophage colony-stimulating factor plusG-CSF. J Clin Oncol 2000;18:1824 –/30.
   Google Scholar
• Akard LP, Thompson JM, Dugan MJ et al . Matched-pair analysisof hematopoietic progenitor cell mobilization using G-CSF vs.cyclophosphamide, etoposide, and G-CSF: enhanced CD34–/cell collections are not necessarily cost-effective. Biol BloodMarrow Transplant 1999;5: 379 –/85.
   Google Scholar
• Cuttler-Fox MH. Mobilizing the older patient with myeloma. In:Broudy VC, Prchal JT, Tricot GJ, editors. Hematology 2003 .American Society of Hematology Education Program Book,Washington DC, 2003:424–/7.
   Google Scholar
• Harrison DE, Astle CM. Loss of stem cell repopulatingability upon transplantation. Effects of donor age, cellnumber, and transplantation procedure. J Exp Med 1882;156: 1767–/79.
   Google Scholar
• Iscove NN, Nawa K. Hematopoietic stem cells expand duringserial transplantation in vivo without apparent exhaustion. CurrBiol 1997;7: 805 –/8.
   Google Scholar
• Allsop RC, Morin GB, DePinho R et al . Telomerase is requiredto slow telomere shortening and extend replicative lifespanof HSCs during serial transplantation. Blood 2003;102: 517–/20.
   Google Scholar
• Hornung RL, Longo DL. Hematopoietic stem cell depletion byrestorative growth factor regimens during repeated high-dosecyclophosphamide therapy. Blood 1992;80: 77–/83.
   Google Scholar
• Lataillade JJ, Clay D, Dupuy C et al . Chemokine SDF-1enhances circulating CD34–/ cell proliferation in synergywith cytokines: possible role in progenitor survival. Blood2000;95: 756 –/68.
   Google Scholar